The Board considered and adopted the unaudited financial results for the quarter ended June 30, 2026

Regd. Office & Factory Corporate Office Plot No. A2/3444-3445, GIDC, 701/702, Business Square, Phase 4, Ankleshwar – 393 002 M.A. Road, Andheri (West), Gujarat, India Mumbai – 400 058, India Tel : +91-7045456789 / 7046456789 Tel : +91-7507534567 / 8760345678 Web: www.samratpharmachem.com CIN: L24230GJ1992PLC017820 Email: contact@samratpharmachem.in August 14, 2026 Department of Corporate Services, BSE Limited P J Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 530125 Dear Sir, Sub: Outcome of the Board Meeting of the Company held today We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, August 14, 2026, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2026, which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company. The meeting of the Board of Directors of the Company commenced at 14:00 hours and concluded at 20:00 hours. Kindly inform all your members. Thanking you, Yours faithfully, For Samrat Pharmachem Limited Nishant Kankaria Company Secretary & Compliance Officer Samrat Pharmachem Limited Regd Office : Plot No. A2/3444-3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com) Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820) Statement of standalone unaudited financial results for the quarter ended June 30, 2026 (Currency : Indian Rupees in lakhs) Quarter ended Year ended 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 (Unaudited) (Unaudited) (Unaudited) (Audited) A Continuing Operations I INCOME a) Revenue From Operations 7,976.10 7,177.32 7,565.16 28,972.12 b) Other Income 98.82 (30.67) 69.13 83.37 Total Income 8,074.92 7,146.65 7,634.29 29,055.49 II EXPENSES a) Cost of Material Consumed 7,830.88 7,038.07 8,251.71 28,966.68 b) Purchase of Traded Goods - - - - c) Changes in inventories ( 147.32) 34.61 ( 912.71) ( 662.02) d) Employee benefits expense 50.54 68.80 50.78 227.60 e) Finance costs 11.38 13.65 43.79 95.53 f) Depreciation and amortisation expense 18.80 18.55 17.00 71.98 g) Other expenses 152.11 160.30 162.94 653.82 Total expenses 7,916.39 7,333.98 7,613.51 29,353.59 III Profit before tax before exceptional items (I - II) 158.53 (187.33) 20.78 (298.10) IV Exceptional item income - - - - Profit before tax after exceptional items (III + IV) 158.53 (187.33) 20.78 (298.10) VI Tax expense a) Current tax 19.00 - - 0.09 b) Deferred tax 51.94 16.30 43.58 30.05 c) Short / (Excess) provision for tax - prior years ( 0.01) - 0.09 2.96 Total Tax 70.93 16.30 43.67 33.10 VII Profit for the year (V - VI) 87.60 (203.63) (22.89) (331.20) VIII Other Comprehensive Income (a) Items that will not be reclassified to profit or loss Remeasurement (losses) / gains on defined benefit obligations - - - - (net) Income tax on above credit / (charge) - - - - Total (a) - - - - (b) Items that will be reclassified to profit or loss - - - - Income tax on above credit / (charge) - - - - Total (b) - - - - Total other comprehensive (loss) / income - - - - IX Total Comprehensive Income for the year (VII + VIII) 87.60 (203.63) (22.89) (331.20) X Basic and diluted earnings per equity share in Rupees 2.84 ( 6.59) ( 0.74) ( 10.72) (Face value Rs. 10 each) * * Not annualised for period less than one year Notes: 1. The above results were reviewed by the Audit Committee of the Board of Directors. 2. The above results have been taken on record by the Board of Directors at it Meeting held on Friday, August 14, 2026 at the Corporate Office of the Company. 3. The Company manufactures pharmaceutical chemicals, which is a single business segment. 4. The figures for the previous period have been regrouped where necessary to conform to current period's classification. By order of the Board of Directors For Samrat Pharmachem Limited Place: Mumbai Date: August 14, 2026 Lalit Mehta Chairman & Managing Director